AI-generated summary
The authors studied 13 people with Alzheimer's disease or minimal cognitive impairment over 12 weeks, comparing at-home 810 nm LED photobiomodulation with a sham treatment. They report that the treated group showed a larger change on the DAD functional questionnaire, while anxiety and depression scores did not differ significantly between groups. The authors describe the approach as promising but call for larger studies.
- Participants
- 13
- Who or what was studied
- Individuals with Alzheimer's disease and minimal cognitive impairment in Iran (6 intervention, 7 sham control)
- Wavelengths
- 810 nm
- Limits stated in the abstract
- The very small sample of 13 patients and the authors' own call for larger sample sizes and cautious interpretation limit the strength of the findings.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Control group, Mild cognitive impairment, Light-emitting diode, Sample size, Depression, Wavelength, Dementia. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.